You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 291 No. 9, March 3, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Psychiatry
 •Adverse Effects
 •Alert me on articles by topic

Olanzapine vs Haloperidol for Treatment of Schizophrenia

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We have 2 concerns about the study by Dr Rosenheck and colleagues.1 First, the average dosages of olanzapine (14.1 mg/d) and haloperidol (13.6 mg/d) do not reflect similar levels of dopamine D2 receptor occupancy in each treatment group: about 75% for olanzapine and about 90% for haloperidol.2 Although the dosages that the authors used are common in practice, they do not reflect optimal dosing for haloperidol. Given the relationship between dopaminergic neurotransmission and extrapyramidal symptoms and aspects of cognitive and motor functioning,3 differences in dopamine D2 receptor occupancy could partially explain the small advantages found in favor of olanzapine.

Second, all patients assigned to haloperidol received prophylactic benztropine mesylate, which may negatively modify the expression of tardive dyskinesia4 and may have a negative influence on cognitive functioning.

Comparing olanzapine with optimally dosed haloperidol might shift the balance even more in favor of haloperidol. Such lower doses of . . . [Full Text of this Article]

Lieuwe de Haan, MD, PhD
Academic Medical Centre
Amsterdam, the Netherlands

Nico van Beveren, MD
Erasmus University Medical Centre
Rotterdam, the Netherlands


RELATED ARTICLES

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Jan Volavka and Leslie Citrome
JAMA. 2004;291(9):1064.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
William M. Glazer
JAMA. 2004;291(9):1064-1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Mo Amin and Vijay S. Shukla
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Michal Kunz
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia—Reply
Robert Rosenheck, Deborah Perlick, Stephen Bingham, and Joseph Collins
JAMA. 2004;291(9):1065-1066.
EXTRACT | FULL TEXT  

Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
Robert Rosenheck, Deborah Perlick, Stephen Bingham, Wen Liu-Mares, Joseph Collins, Stuart Warren, Douglas Leslie, Edward Allan, E. Cabrina Campbell, Stanley Caroff, June Corwin, Lori Davis, Richard Douyon, Lawrence Dunn, Denise Evans, Ede Frecska, John Grabowski, David Graeber, Lawrence Herz, Kong Kwon, William Lawson, Felicitas Mena, Javaid Sheikh, David Smelson, and Valerie Smith-Gamble
JAMA. 2003;290(20):2693-2702.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.